|
ZNF101 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.64469999631001E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.61410000038198E-07 |
| Normal-vs-Stage2 |
3.21320003937586E-09 |
| Normal-vs-Stage3 |
1.86999999929327E-08 |
| Normal-vs-Stage4 |
3.89919999621569E-08 |
| Stage1-vs-Stage2 |
3.984900E-03 |
| Stage1-vs-Stage3 |
4.899500E-02 |
| Stage1-vs-Stage4 |
8.917800E-02 |
| Stage2-vs-Stage3 |
3.208800E-01 |
| Stage2-vs-Stage4 |
6.870600E-01 |
| Stage3-vs-Stage4 |
7.136000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.47689999808432E-08 |
| Normal-vs-AfricanAmerican |
1.70089999973477E-07 |
| Normal-vs-Asian |
7.96290000049105E-07 |
| Caucasian-vs-AfricanAmerican |
4.912200E-01 |
| Caucasian-vs-Asian |
7.637000E-01 |
| AfricanAmerican-vs-Asian |
4.491200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.38809999997258E-07 |
| Normal-vs-Female |
4.17690000364956E-08 |
| Male-vs-Female |
4.417000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.74760000049812E-07 |
| Normal-vs-Age(41-60Yrs) |
1.21159999810772E-08 |
| Normal-vs-Age(61-80Yrs) |
3.84239999817737E-08 |
| Normal-vs-Age(81-100Yrs) |
5.549800E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.532350E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.779600E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.971200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.724000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.573800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.762000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.200100E-02 |
| Classical-VS-Follicular |
4.546000E-02 |
| Classical-VS-Other |
2.123600E-01 |
| Classical-VS-Normal |
2.85739999994483E-07 |
| Tall-VS-Follicular |
4.124000E-01 |
| Tall-VS-Other |
7.825400E-01 |
| Tall-VS-Normal |
3.71759999451271E-08 |
| Follicular-VS-Other |
3.488600E-01 |
| Follicular-VS-Normal |
1.93219999999883E-08 |
| Other-VS-Normal |
3.73969999967194E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.57199999578839E-08 |
| Normal-vs-N1 |
2.09469996903522E-09 |
| N0-vs-N1 |
8.499700E-02 |
|
|
